Evogene Ltd. (NASDAQ:EVGN) Short Interest Update

Evogene Ltd. (NASDAQ:EVGN) was the recipient of a large growth in short interest in February. As of February 28th, there was short interest totalling 33,200 shares, a growth of 107.5% from the February 13th total of 16,000 shares. Approximately 0.6% of the company’s shares are short sold. Based on an average daily volume of 41,400 shares, the short-interest ratio is presently 0.8 days.

Evogene Stock Up 3.6 %

Shares of NASDAQ EVGN traded up $0.05 during trading on Friday, reaching $1.43. The company had a trading volume of 11,291 shares, compared to its average volume of 89,204. Evogene has a 12-month low of $1.20 and a 12-month high of $9.00. The business’s 50-day moving average is $1.53 and its 200 day moving average is $1.98. The stock has a market cap of $7.67 million, a PE ratio of -0.32 and a beta of 1.28.

Evogene (NASDAQ:EVGN) last announced its quarterly earnings data on Thursday, March 6th. The biotechnology company reported $0.06 EPS for the quarter, beating the consensus estimate of ($0.72) by $0.78. The company had revenue of $1.61 million for the quarter, compared to the consensus estimate of $3.63 million. Evogene had a negative net margin of 314.43% and a negative return on equity of 109.05%. During the same period in the prior year, the firm posted ($1.30) EPS.

Analyst Upgrades and Downgrades

EVGN has been the topic of a number of research reports. Alliance Global Partners reaffirmed a “buy” rating on shares of Evogene in a research note on Friday, March 7th. StockNews.com initiated coverage on shares of Evogene in a research note on Monday, March 10th. They set a “sell” rating for the company.

Institutional Investors Weigh In On Evogene

An institutional investor recently bought a new position in Evogene stock. Citadel Advisors LLC bought a new position in Evogene Ltd. (NASDAQ:EVGN) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 15,891 shares of the biotechnology company’s stock, valued at approximately $30,000. Citadel Advisors LLC owned about 0.30% of Evogene at the end of the most recent quarter. Hedge funds and other institutional investors own 10.40% of the company’s stock.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.